CYCLO THERAPEUTICS, INC.: 10-Q filed 2016-11-10
What CYCLO THERAPEUTICS, INC. reported in its quarterly report filed 2016-11-10 (fiscal Q3 2016): 27 published measures, 68 facts as tagged in accession 0001213900-16-018214.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-11-10
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001213900-16-018214 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 3,233,927 | USD | |
| At 2015-12-31 | 4,690,829 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,357,979 | USD | |
| At 2015-12-31 | 3,745,683 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,270,046 | USD | |
| At 2015-12-31 | 1,842,233 | USD | |
| At 2015-09-30 | 2,742,417 | USD | |
| At 2014-12-31 | 2,380,054 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -1,614,933 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -3,391,865 | USD | 274 |
| 2015-01-01 to 2015-12-31 | 2,551,000 | USD | 365 |
| 2015-07-01 to 2015-09-30 | -747,556 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -1,495,992 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | -2,386,557 | USD | 274 |
| 2015-01-01 to 2015-12-31 | 1,989,000 | USD | 365 |
| 2015-01-01 to 2015-09-30 | -1,166,564 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 9,343 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 337,884 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 1,799,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 1,866,111 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 15,370 | USD | 274 |
| 2015-01-01 to 2015-09-30 | -337,184 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -8,667,631 | USD | |
| At 2015-12-31 | -5,275,766 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 33,691 | USD | |
| At 2015-12-31 | 1,892,943 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 57,114 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -1,610,730 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -3,377,752 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -740,182 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -1,475,080 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,018,552 | USD | |
| At 2015-12-31 | 2,522,886 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 6,969 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 21,722 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 7,749 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 23,527 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 875,948 | USD | |
| At 2015-12-31 | 945,146 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 124,234 | USD | |
| At 2015-12-31 | 55,636 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 595,366 | USD | |
| At 2015-12-31 | 610,166 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 311,351 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 1,254,900 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 221,362 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 399,427 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 66,952,529 | shares | |
| At 2015-12-31 | 58,670,347 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 11,018,915 | USD | |
| At 2015-12-31 | 9,015,582 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 673,033 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,181,684 | USD | |
| At 2015-12-31 | 275,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -1,614,933 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -3,391,865 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -747,556 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -1,495,992 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 92,146 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 124,990 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -4,203 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -14,113 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -7,374 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -20,912 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 68,598 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 33,279 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | -19,758 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 63,941 | USD | 273 |
Inspect the source
- Entity
- CYCLO THERAPEUTICS, INC. / CIK 0000922247
- Captured
- 2026-09-21T17:17:43.874Z
- SEC response SHA-256
00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))